HiberCell, a clinical-stage biotechnology company, announced the presentation of preclinical data demonstrating the enhanced antitumor activity of its GCN2 activator HC-7366 in combination with VEGFR-TKIs in clear cell renal cell carcinoma (ccRCC) models.
The data, to be presented at the AACR Annual Meeting 2026, show that HC-7366 enhanced the activity of multiple VEGFR-TKIs, including lenvatinib, cabozantinib, and axitinib, with the HC-7366 and VEGFR-TKI doublets outperforming the combination of HIF-2α inhibitor and VEGFR-TKI in several preclinical patient-derived xenograft models.
The findings support HC-7366 as a potential strategy to overcome VEGFR-TKI resistance in metastatic ccRCC and provide rationale for clinical evaluation of HC-7366 and VEGFR-TKI combinations in ccRCC. This builds on previous data presented at AACR 2024 demonstrating the combination potential of HC-7366 with HIF-2α inhibitors, further supporting HiberCell's ongoing clinical evaluation of HC-7366 in combination with the three major standard-of-care therapeutic classes in ccRCC.
AACR 2026 Poster Presentation Highlights
The poster presentation will highlight data showing that HC-7366 enhanced the activity of multiple VEGFR-TKIs, including lenvatinib, cabozantinib, and axitinib, in preclinical metastatic ccRCC models. The HC-7366 and VEGFR-TKI doublets outperformed the combination of HIF-2α inhibitor and VEGFR-TKI in several preclinical patient-derived xenograft models. These findings support HC-7366 as a potential strategy to overcome VEGFR-TKI resistance in metastatic ccRCC and provide rationale for clinical evaluation of HC-7366 and VEGFR-TKI combinations in ccRCC.
The poster will be presented at the AACR Annual Meeting 2026, taking place April 17-22 in San Diego, California. HiberCell recently initiated a Phase 1b arm evaluating HC-7366 in combination with cabozantinib in metastatic ccRCC as part of its ongoing clinical study (NCT06234605).
“We're excited to share these data, which demonstrate the preclinical combination potential of HC-7366 with VEGFR-TKIs, a key standard-of-care therapeutic class in ccRCC. These findings build on the data presented at the 2024 AACR Annual Meeting demonstrating the combination potential of HC-7366 with HIF-2α inhibitors and further support our ongoing clinical evaluation of HC-7366 in combination with all three major standard-of-care therapeutic classes in ccRCC: HIF-2α inhibitors, VEGFR-TKIs, and immune checkpoint inhibitors. Collectively, these data suggest HC-7366 may have the potential to emerge as a next-generation, novel therapeutic approach in ccRCC.”
The Players
HiberCell, Inc.
A clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance.
HC-7366
A first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase, which is currently under clinical development in Phase 1b studies in ccRCC and acute myeloid leukemia (AML).
